1. Home
  2. AIFF
  3. AIFF News

Latest FIREFLY NEUROSCIENCE INC (AIFF) News on November 22, 2024

Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)
AIFF

Simply Wall St.

6 days ago

Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
AIFF

GlobeNewswire

8 days ago

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
AIFF

GlobeNewswire

16 days ago

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AIFF

GlobeNewswire

a month ago

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
AIFF

GlobeNewswire

a month ago

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
AIFF

GlobeNewswire

a month ago

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder
AIFF

GlobeNewswire

a month ago

Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder

Firefly Neuroscience to Participate in Upcoming October Investor Conferences
AIFF

GlobeNewswire

a month ago

Firefly Neuroscience to Participate in Upcoming October Investor Conferences

Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
AIFF

GlobeNewswire

2 months ago

Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis

Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
AIFF

GlobeNewswire

2 months ago

Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform

Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
AIFF

GlobeNewswire

3 months ago

Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors

Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
AIFF

GlobeNewswire

3 months ago

Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11

Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
AIFF

GlobeNewswire

3 months ago

Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th

Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
AIFF

GlobeNewswire

3 months ago

Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders

Share on Social Networks: